Sep 24 2026
/
Primary Market Research in Pharma: Turning Stakeholder Perspectives into Actionable Decisions
In pharma, more data doesn’t always mean better answers.
Secondary research can tell a team what has happened in a market, such as prescription trends, treatment shares, clinical developments, competitor activity, patient populations, and market size. But when a commercial, medical, development, or market access team needs to understand why stakeholders behave the way they do and what they may do next, another layer of insight is needed.
That is where Primary Market Research (PMR) becomes critical. By directly engaging physicians, patients, caregivers, payers, and other relevant stakeholders, PMR brings the market closer to the people making and experiencing treatment and access decisions.
At Thelansis, we use primary research to answer the questions that secondary data alone cannot, such as what stakeholders need, what influences their decisions, how they perceive an emerging therapy, where barriers exist, and how those insights should shape decisions across the asset lifecycle.
What Is Primary Market Research?
Primary Market Research is the structured collection of first-hand information directly from relevant market stakeholders. Depending on the business question, this can include quantitative surveys, qualitative interviews, concept testing, advisory boards, message testing, pricing and access research, ATU studies, patient research, KOL engagement, and longitudinal tracking.
The value of PMR is not simply in collecting opinions. Well-designed research connects stakeholder feedback with a specific business question and translates it into evidence that teams can use.
For example:
- What makes a physician choose one treatment over another?
- What prevents a patient from starting or remaining on therapy?
- Which attributes of a new treatment matter most to physicians?
- How do payers perceive the clinical and economic value of an emerging therapy?
- Which messages are credible, differentiated, and relevant?
- How might treatment preferences change after a competitor enters the market?
These questions require more than market statistics. They require listening to the people who influence, deliver, pay for, or experience treatment.
Why Is PMR Essential?
Secondary data tells you what happened. PMR helps explain why and what stakeholders may do next. A market can show declining prescriptions, but secondary data alone may not explain whether the decline is driven by efficacy concerns, tolerability, reimbursement restrictions, physician confidence, treatment convenience, patient preferences, or the arrival of a competing therapy.
PMR Adds That Missing Context:
Understand stakeholder needs
Prescribing, treatment choice, adherence, and access decisions are shaped by multiple factors, including physician confidence, patient preferences, treatment experience, perceived clinical value, and access friction. PMR provides direct insight into these drivers and helps distinguish what stakeholders say matters from what actually influences their decisions.
De-risk commercial and access decisions
Launch planning, message development, positioning, pricing, and access strategy involve decisions with significant commercial implications. Testing these assumptions with relevant stakeholders before major decisions are committed can identify potential barriers, refine the value proposition, and highlight areas where expectations may differ from market reality.
Bring the stakeholder voice into strategic decisions
A product strategy should not be developed in isolation from the people it ultimately needs to serve. Physician, patient, caregiver, and payer perspectives can provide important context for product development, positioning, value communication, patient support, and market access planning. The objective is not simply to collect feedback. It is to ensure that stakeholder perspectives are incorporated into strategic decision-making.
Move beyond point-in-time research
Markets do not stand still. Competitive entries, label changes, emerging clinical evidence, treatment experience, pricing developments, and access changes can alter stakeholder perceptions over time.
Longitudinal and tracking research can help teams identify these shifts rather than relying on a single snapshot of market sentiment.
Accelerate research without compromising rigor
Technology and AI are changing how research is conducted. AI-enabled tools can support survey scripting, transcription, coding, data processing, respondent screening, and synthesis, helping research teams work more efficiently.
But faster research does not automatically mean better research. The quality of PMR still depends on sound methodology, appropriate sampling, experienced moderation, robust questionnaire design, statistical validation, and disciplined interpretation. Technology can accelerate the process. Research rigor determines the quality of the insight.
Our PMR Framework: From Early Development to Lifecycle Management
At Thelansis, we view PMR as an ongoing strategic capability rather than a one-time research exercise. The questions change as an asset progresses. So does the stakeholder mix, research methodology, and type of decision the research needs to support.
Stage 1: Early Development / Pre-Clinical to Phase II
The question we help answer: “What does the market actually need, and who are we building this for?”
Early-stage research can help development teams understand the treatment landscape before positioning becomes fixed. Our work can include:
- Early market landscaping and unmet-need assessment
- Physician and patient concept testing
- Target Product Profile (TPP) input from a stakeholder perspective
- Disease-burden and patient-journey research
- Early treatment-driver and preference research
At this stage, the objective is to understand where meaningful unmet needs exist and which product attributes could matter most to stakeholders.
Early stakeholder input can also help identify assumptions that may need to be challenged before development progresses further.
Stage 2: Late-Stage Development / Pre-Launch
The question we help answer: “Will physicians prescribe it, will patients want it, and will payers pay for it?”
As an asset approaches launch, the focus shifts from understanding the opportunity to testing commercial and access assumptions. Thelansis supports research across:
- Message and positioning testing
- Awareness, Trial and Usage (ATU) and prescribing-intent studies
- Payer research
- Pricing and access research
- Value proposition testing
- Advisory-board input on launch readiness
Research at this stage can help identify differences between how a brand team expects a product to be perceived and how stakeholders actually respond to it. That distinction can be important when refining the product story, communication strategy, pricing assumptions, and access approach.
Stage 3: Launch
The question we help answer: “Is the launch landing the way we expected, and where do we need to adjust?”
Launch does not mark the end of stakeholder research. In many ways, it is when market assumptions begin to meet real-world experience. Our launch-stage PMR can include:
- Early launch tracking
- Awareness, trial, and prescribing-behavior research
- Physician and patient feedback on messaging and access
- Competitive benchmarking
- KOL and advisory-board engagement
- Brand and positioning assessment
These insights can help teams understand whether awareness is translating into consideration and whether intended positioning is reflected in actual stakeholder perceptions.
Stage 4: Post-Launch / Lifecycle Management
The question we help answer: “Is stakeholder sentiment holding, and what is changing in the competitive landscape?”
Post-launch markets continue to evolve. New evidence, competitors, label expansions, treatment experience, changing guidelines, pricing dynamics, and access conditions can all influence stakeholder behavior. Thelansis supports ongoing research through:
- ATU and brand-health tracking
- Patient experience and adherence research
- Competitive response and market-shift assessment
- Stakeholder sentiment tracking
- Panel-based re-engagement for label expansions or new indications
- Lifecycle strategy research
The goal is to maintain an evidence-based understanding of the market and identify changes early enough to inform lifecycle decisions.
Where This Makes a Difference
Consider a mid-sized asset approaching a competitive launch. Secondary data shows prescribing trending flat among target specialists, but doesn’t say why. A short round of message and positioning testing with that physician segment can reveal, for instance, that the core efficacy message isn’t the barrier; tolerability concerns and unclear dosing guidance are. That distinction changes what the launch team fixes first: the message, or the materials that support it. This is the kind of directional clarity PMR is built to deliver, not just confirming a hypothesis, but correcting it before it becomes an expensive one.
The Questions We Help Answer
Across the asset lifecycle, our PMR work is designed around the decisions our clients need to make. We help teams explore questions such as:
- What do physicians, patients, and payers actually need, not simply what we assume they need?
- What drives treatment choice, prescribing, switching, adherence, and access?
- How will stakeholders respond to our messaging, pricing, and positioning before we commit to them?
- Where is prescribing or access behavior diverging from what secondary data suggests?
- What are the barriers to adoption, and where are the opportunities to improve uptake?
- How is stakeholder sentiment changing over time?
- How does the competitive landscape influence treatment and access decisions?
- Which product attributes and messages create meaningful differentiation?
- How do stakeholders perceive the clinical and economic value of an emerging therapy?
- How can fielded research be translated into insights that commercial, medical, development, and market access teams can act on?
From Research Data to Strategic Insight
The value of PMR is ultimately determined by what happens after the interviews are completed and the survey closes. Collecting responses is only one part of the process. The real value comes from connecting stakeholder feedback with market context, identifying meaningful patterns, testing assumptions, and translating findings into clear implications for the business.
At Thelansis, our approach combines primary research expertise, therapeutic-area understanding, structured analysis, and strategic interpretation to help clients move from stakeholder feedback to actionable decisions. Because the most useful PMR does not simply answer:
What did stakeholders say?
It helps answer:
What does it mean for our strategy, and what should we consider next?
Thelansis Bringing the Market Voice into Every Stage of the Asset Lifecycle
Primary Market Research is most valuable when it is connected to the decisions that matter. From early unmet-need exploration and TPP development to pre-launch positioning, launch tracking, pricing and access, and post-launch lifecycle strategy, Thelansis helps organizations bring the stakeholder voice into the decision-making process.
Markets are made up of people and understanding what they think, what drives their decisions, and how those views can evolve is just as important as knowing what the numbers say.
Planning a study, or want to talk through where PMR fits into your asset’s current stage? Get in touch with the Thelansis team to discuss your research needs.